EGFR mutation-positive NSCLC

URI: https://gptkb.org/entity/EGFR_mutation-positive_NSCLC
GPTKB entity
Statements (30)
Predicate Object
gptkbp:instanceOf gptkb:non-small_cell_lung_cancer_subtype
gptkbp:diagnosedBy molecular testing
gptkbp:hasApprovedDrug gptkb:afatinib
gptkb:erlotinib
gptkb:gefitinib
gptkb:osimertinib
gptkbp:hasBiomarker EGFR protein overexpression
gptkbp:hasFirstLineTherapy gptkb:osimertinib
gptkbp:hasGeneticAlteration gptkb:EGFR_mutation
gptkbp:hasResistanceMechanism HER2 amplification
MET amplification
small cell transformation
gptkbp:hasResistanceMutation gptkb:T790M_mutation
gptkbp:hasSecondLineTherapy chemotherapy
gptkbp:hasTargetedTherapy gptkb:EGFR_tyrosine_kinase_inhibitor
gptkbp:incidence 10-15% in Western populations
30-50% in Asian populations
gptkbp:mutationAssociatedWith gptkb:L858R_mutation
exon 19 deletion
gptkbp:prevalence gptkb:East_Asian_populations
females
non-smokers
gptkbp:prognosis generally better than EGFR wild-type NSCLC
gptkbp:subspecies gptkb:lung_adenocarcinoma
gptkbp:treatment gptkb:targeted_therapy
chemotherapy
immunotherapy (less effective)
gptkbp:bfsParent gptkb:Tagrisso
gptkbp:bfsLayer 7
https://www.w3.org/2000/01/rdf-schema#label EGFR mutation-positive NSCLC